Jazz Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell JAZZ and other ETFs, options, and stocks.About JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.
JAZZ Key Statistics
Stock Snapshot
As of today, Jazz Pharmaceuticals(JAZZ) shares are valued at $185.40. The company's market cap stands at 11.41B, with a P/E ratio of -31.05.
On 2026-03-10, Jazz Pharmaceuticals(JAZZ) stock moved within a range of $178.01 to $186.22. With shares now at $185.40, the stock is trading +4.2% above its intraday low and -0.4% below the session's peak.
Trading activity shows a volume of 715.27K, compared to an average daily volume of 1.39M.
Over the past 52 weeks, Jazz Pharmaceuticals(JAZZ) stock has traded between a high of $198.00 and a low of $95.49.
Over the past 52 weeks, Jazz Pharmaceuticals(JAZZ) stock has traded between a high of $198.00 and a low of $95.49.
JAZZ News
In February 2026, Jazz Pharmaceuticals reported fourth-quarter 2025 results showing revenue rising to US$1.20 billion and net income of US$203.45 million, while...
New insider activity at Jazz Pharmaceuticals ( (JAZZ) ) has taken place on March 9, 2026. Senior Vice President and Chief Accounting Officer Patricia Carr has...
Jazz Pharmaceuticals reported record revenues for 2025 and highlighted strong Q4 results. The company completed regulatory filing for zanidatamab in gastroesop...
Analyst ratings
83%
of 18 ratingsMore JAZZ News
Advertisement Recent performance snapshot for Jazz Pharmaceuticals (JAZZ) Jazz Pharmaceuticals (JAZZ) has attracted attention after a period of mixed short te...